Utility Menu French

National Association of Pharmacy Regulatory Authorities

Provinces French

Main navigation French


Recherchez dans la Base de données des annexes nationales de médicaments

Commencez votre recherche en utilisant le nom générique du produit :

Recherche par annexe
Réinitialiser

ATTENTION : Tous les résultats de la recherche seront tirés du « National Drug Schedules » du site Web en anglais.

Nom du médicament (en anglais) Commentaire Annexe Date
EcgonineN I JUN / 02
Econazole and its saltsF1 I SEP / 98
Ecothiophate and its saltsF2 I SEP / 98
Ectylurea and its saltsF1 I SEP / 98
EculizumabF1 I MAR / 11
Edoxaban or its saltsPDL I FEB / 17
Edrophonium chlorideF1 I SEP / 98
EfavirenzF1 I MAY / 00
Eflornithine and its salts and derivativesF1 I JUL / 03
Elbasvir or its saltsPDL I AUG / 16
Electrolyte solutions for oral rehydration III SEP / 98
Eletriptan and its saltsF1 I FEB / 07
Eliglustat or its saltsPDL I MAY / 17
Elosulfase alfaPDL I AUG / 14
ElotuzumabPDL I AUG / 16
Eltrombopag or its saltsPDL

including but not limited to eltrombopag olamine

I DEC / 13
Eluxadoline or its saltsPDL I APR / 17
EmbutramideF1 I SEP / 98
Emedastine and its saltsF1 I SEP / 99
EmpagliflozinPDL I OCT / 15
EmtricitabineF1 I FEB / 07
EmylcamateF1 I SEP / 98
Enalaprilat and its salts and derivativesF1 I SEP / 98
Encephalitis vaccine (Japanese) I FEB / 02
EnestebolC3 I JUN / 02
EnfluraneF1 I SEP / 98
EnfuvirtideF1 I JUN / 06
Enoxaparin and its saltsF1 I SEP / 98
EnrofloxacinF1 I SEP / 98
EntacaponeF1 I JUL / 03
EntecavirF1 I OCT / 07
Ephedrine and its salts in preparations containing more than 8 mg per unit dose, or with a label recommending more than 8 mg/dose or 32 mg/day, or labelled or implied for use exceeding 7 days, or if indicated for other than nasal congestion. I FEB / 02
Ephedrine and its salts in combination products in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. III APR / 06
Ephedrine and its salts in single entity products. in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. II APR / 06
Epinephrine and its salts in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens II SEP / 99
Epinephrine and its salts. other than in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens I SEP / 99
Epirubicine and its saltsF1 I SEP / 98
EpitiostanolC3 I JUN / 02
EplerenonePDL I DEC / 13
EpsiprantelF1 I MAY / 00
Ergot alkaloids and their saltsF2 I SEP / 98
Eribulin or its salts or derivativesPDL

including but not limited to eribulin mesylate

I DEC / 13
Erlotinib and its saltsF1 I OCT / 07
Ertapenem and its saltsF1 I JUN / 06
Erythrityl tetranitrate I SEP / 98
Erythromycin and its salts and derivativesF2 I SEP / 98
ErythropoietinF1 I SEP / 98
Escitalopram and its saltsF1 I FEB / 07
Esdepallethrin/piperonyl butoxide II SEP / 98
Eslicarbazepine acetatePDL I AUG / 14
Esmolol and its saltsF1 I SEP / 98
Esomeprazole or its salts except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes of no more than 280 mg of esomeprazole I AUG / 16
Esomeprazole or its salts. when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole II AUG / 16
Estazolam and its saltsTS I SEP / 98
Estramustine and its saltsF1 I SEP / 98
EtanerceptF1 I JUL / 03
Ethacrynic acidF1 I SEP / 98
Ethambutol and its saltsF1 I SEP / 98
Ethanolamine oleate II SEP / 98
EthchlorvynolTS I SEP / 98
EthinamateTS I SEP / 98
Ethionamide and its saltsF1 I SEP / 98
Ethoheptazine and its salts II SEP / 98
Ethomoxane and its saltsF1 I SEP / 98
Ethopropazine hydrochlorideF1 profenamine and its salts I SEP / 98
Ethotoin and its saltsF1 I SEP / 98
Ethyl Chloride except in trace amounts II SEP / 98
Ethyl LoflazepateTS I JUN / 02
Ethyl trichloramateF1 I SEP / 98
EthylestrenolC3 I JUN / 02
EthylmethylthiambuteneN I JUN / 02
EthylmorphineN I JUN / 02
Ethylpapaverine and its salts I SEP / 98
Etidronic acid and its saltsF1 I SEP / 98
Etodolac and its salts and derivativesF1 I SEP / 98
EtonitazeneN I JUN / 02
Etoposide and its derivativesF1 I SEP / 98
EtorphineN I JUN / 02
EtoxeridineN I JUN / 02
Etravirine and its saltsF1 I OCT / 09
EtretinateF1 I SEP / 98
Etryptamine and its saltsF1 I SEP / 98
Etymemazine and its saltsF1 I SEP / 98
EvolocumabPDL I JAN / 16
ExemestaneF1 I DEC / 02
Exenatide or its saltsPDL I DEC / 13
EzetimibeF1 I JUN / 06

87 résultats


Footnotes

  • C1: Drug is in the Controlled Drugs and Substances Act and Part I of the Schedule to Part G of the Food and Drug Regulations}
  • C2: Drug is in the Controlled Drugs and Substances Act and Part II of the Schedule to Part G of the Food and Drug Regulations
  • C3: Drug is in the Controlled Drugs and Substances Act and Part III of the Schedule to Part G of the Food and Drug Regulations
  • C4: drug is in the Controlled Drugs and Substances Act
  • C5: drug is in the Regulations Under CDSA
  • CR: drug has been recommended for addition to the Controlled Drugs and Substances Act
  • CR-C: drug has been recommended for addition to the Controlled Drugs and Substances Act, Part G of the Food and Drug Regulations
  • CR-N: drug has been recommend for addition to the Controlled Drugs and Substances Act, Narcotic Control Regulations
  • CR-TS: drug has been recommended for addition to the Controlled Drugs and Substances Act, Benzodiazepines and Other Targeted Substances Regulations
  • F1: drug appears in Part I of Schedule F to the Food and Drugs Act and Regulations
  • F2: drug appears in Part II of Schedule F to the Food and Drugs Act and Regulations
  • FR: drug has been recommended for addition to Schedule F to the Food and Drugs Act and Regulations ("Schedule F Recommended")
  • N: drug is in the Narcotic Control Regulations under the Controlled Drugs and Substances Act
  • NR: drug has not been reviewed by NDSAC
  • PDL: drug is in the Prescription Drug List (effective Dec. 19, 2013)
  • R: drug is in Part J of the Food and Drus Act and listed in the Controlled Drugs and Substances Act
  • TS: drug is in the Benzodiazepines and Other Targeted Substances Regulations under the Controlled Drugs and Substances Act
  • U: drug has been reviewed by NDSAC and is unscheduled